NCT03431623View on ClinicalTrials.gov

CKD-11101 Phase 3 SC Study

PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

August 31, 2017

Conditions
Anemia of Chronic Kidney Disease
Interventions
BIOLOGICAL

CKD-11101(Darbepoetin alfa)

BIOLOGICAL

NESP(Darbepoetin alfa)

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY